Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications December 8, 2025 8:00 PM EST

Company Participants

Nadim Ahmed - President, CEO & Director Jeffrey Jones - Chief Medical Officer

Conference Call Participants

David Sallman Marc Frahm - TD Cowen, Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Robert Driscoll - Wedbush Securities Inc., Research Division Justin Zelin - BTIG, LLC, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Bradley Canino - Guggenheim Securities, LLC

Presentation

Nadim Ahmed President, CEO & Director

All right. Good evening, everyone. Thanks for coming as we look forward to discussing the compelling initial results for CLN-049 that were presented at ASH today and also look forward to the promise of CLN-049 for patients with AML.

So our disclosure slide. So as outlined in the slide, during this event, management will be making certain forward-looking statements. Please consult the risk factors discussed in our SEC filings for additional uncertainties that may cause the actual results to differ.

All right. Glad to get that one out of the way. Okay. So turning to this evening. I’m very pleased to welcome Dr. Jeff Jones, our Chief Medical Officer, and we’re especially pleased to welcome Dr. David Sallman from the Moffitt Cancer Center, where he’s Associate Member, a Myeloid Section Head, also the research institute. And now not only is Dr. Sallman a leading investigator in our study, he’s also a leading researcher in the field of p53-mutated AML and MDS, which you’ll see is very, very important for the content today.

So I’m going to start out by outlining our broad pipeline strategy as a company. Jeff will then recap the results for 049 that were presented today and also talk about immediate next steps for development. Dr. Sallman is going to cover the current

Recommended For You